* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Joinn Laboratories (China) Co's PEG Ratio or its related term are showing as below:
HKSE:06127'
s PEG Ratio Range Over the Past 10 Years
Min: 0.47 Med: 1.2 Max: 4.14
Current: 2.19
During the past 12 years, Joinn Laboratories (China) Co's highest PEG Ratio was 4.14. The lowest was 0.47. And the median was 1.20.
HKSE:06127's PEG Ratio is ranked worse than 63.16% of 57
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.69
vs HKSE:06127: 2.19
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Joinn Laboratories (China) Co PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Joinn Laboratories (China) Co's PEG Ratio
For the Diagnostics & Research subindustry, Joinn Laboratories (China) Co's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Joinn Laboratories (China) Co's PEG Ratio Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Joinn Laboratories (China) Co's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Joinn Laboratories (China) Co's PEG Ratio falls into.
Joinn Laboratories (China) Co PEG Ratio Calculation
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio.
The ratio we use is the 5-Year EBITDA growth rate.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Joinn Laboratories (China) Co (HKSE:06127) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Joinn Laboratories (China) Co PEG Ratio Related Terms
Thank you for viewing the detailed overview of Joinn Laboratories (China) Co's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Joinn Laboratories (China) Co (HKSE:06127) Business Description
Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non- Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.
Joinn Laboratories (China) Co (HKSE:06127) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:06127 has been successfully added to your 